Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomas.

ABSTRACT:

Purpose

Molecular classification of endometrial cancer (EC) has emerged as a key approach to individualize therapy and define prognostic outcomes. This study aimed to implement the traditional ProMisE classification in a Brazilian population, compared with a molecular setting of ProMisE biomarkers, and evaluate its impact on patients' prognosis.

Patient and methods

A prospective cohort of 114 patients with primary EC treated at Barretos Cancer Hospital (BCH) between October 2020 and December 2022 was conducted. Pathology diagnosis, staging, treatment, and follow-up data were collected. The traditional ProMisE methodology was carried out by POLE hotspot sequencing and immunohistochemistry (IHC) for p53 and mismatch repair (MMR) proteins. We further evaluate the MMR and

SUBMITTER: Andrade DAP 

PROVIDER: S-EPMC11671357 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature